422.2 ð åèçïŒé«åž«åè / PGY OSCEïŒ
422.2.0.1 ð Cram Sheet
422.2.0.1.1 ð¥ é« yield 15
- Ca homeostasis: PTH + 1,25-Vit D + FGF-23
- PTH effects: bone resorption â + renal Ca reabsorb â + 1α-OH â + P excretion â
- Vit D activation: skin/diet â liver 25-OH â kidney 1α-OH (PTH-stim) â 1,25-D
- 25-D = storage marker; 1,25-D = active (kidney activation)
- FGF-23: P excretion + 1,25-D inhibitor
- Osteoporosis: T-score †-2.5 OR fragility fracture
- Bisphosphonate 1st line: alendronate, risedronate, ibandronate, zoledronic acid
- Denosumab: anti-RANK-L Q6mo SC
- Teriparatide / abaloparatide: PTH analog anabolic Q1d à 2 yr
- Romosozumab: anti-sclerostin 12 monthly doses (22E; CV caveat)
- Sequential: anabolic â anti-resorptive (severe)
- Denosumab æ¥å rebound â must bridge to bisphosphonate
- Glucocorticoid = #1 secondary cause osteoporosis
- Pagetâs: ALP âââ + zoledronic acid
- CKD-MBD: phosphate binder + activated Vit D + cinacalcet
422.2.0.1.2 ð¢ å¿ è
| é ç® | æžå |
|---|---|
| Total Ca normal | 8.5-10.5 mg/dL |
| Ionized Ca normal | 4.4-5.2 mg/dL |
| Phosphate normal | 2.5-4.5 mg/dL |
| 25-D deficiency | < 20 ng/mL |
| 25-D insufficient | 21-29 |
| 25-D sufficient | 30-100 |
| T-score osteoporosis | †-2.5 |
| T-score osteopenia | -1 to -2.5 |
| Calcium daily intake | 1200 mg |
| Vit D daily | 800-2000 IU |
| Albumin Ca correction | + 0.8 Ã (4 â albumin) |
| Bisphosphonate holiday oral | 5 yr |
| Bisphosphonate holiday IV | 3 yr |
| Denosumab dosing | Q6 mo SC |
| Teriparatide duration | 2 yr lifetime |
| Romosozumab duration | 12 monthly doses |
422.2.0.2 â é« yield
422.2.0.2.1 Bone Cells Quick
| Cell | Function | Marker |
|---|---|---|
| Osteoblast | Build bone | Bone-ALP, P1NP |
| Osteocyte | Mature, mechanosensor, sclerostin | â |
| Osteoclast | Resorb bone | CTX, NTX, TRAP |
422.2.0.2.2 Bone Drug by Mechanism
| Drug | Mechanism |
|---|---|
| Alendronate, risedronate, ibandronate, zoledronic acid | Bisphosphonate (osteoclast apoptosis) |
| Denosumab | Anti-RANK-L (block osteoclast formation) |
| Teriparatide (PTH 1-34) | Anabolic (intermittent PTH stim osteoblast) |
| Abaloparatide (PTHrP analog) | Anabolic |
| Romosozumab | Anti-sclerostin (anabolic + anti-resorptive) |
| Raloxifene | SERM (bone agonist + breast antagonist) |
| Calcitonin | Anti-resorptive (limited efficacy) |
| Strontium ranelate | Anabolic + anti-resorptive (limited use due to CV risk) |
422.2.0.2.3 Osteoporosis Causes
- Primary: postmenopausal (Type 1), senile (Type 2)
- Secondary:
- Glucocorticoid (#1)
- Hypogonadism, hyperthyroid, hyperPTH
- Vit D def
- CKD
- Celiac, IBD, bariatric
- MM, leukemia
- Anorexia, FHA
- PPI, SSRI, aromatase inhibitor, GnRH agonist, anticonvulsant, heparin
- Smoking, alcohol
422.2.0.2.4 Vit D Causes Deficiency
- Insufficient sunlight
- Diet
- Malabsorption (celiac, IBD, bariatric)
- CKD (1α-OH â)
- Liver disease (25-OH â)
- Drugs: phenytoin, rifampin, anti-retroviral
- Obesity (sequestration)
- Granulomatous: 1,25-D âââ â hyperCa (paradox)
422.2.0.3 ð¯ èªææª¢æž¬
- PTH 4 effects? â Bone resorb + Ca reabsorb + 1α-OH + P excrete
- 25-D vs 1,25-D? â 25-D storage; 1,25-D active
- FGF-23? â P excrete + 1,25-D inhibitor
- Osteoporosis T-score? â †-2.5
- Calcium daily? â 1200 mg
- Vit D deficiency? â < 20 ng/mL
- Albumin Ca correction? â + 0.8 Ã (4 â albumin)
- Bisphosphonate 1st? â Alendronate weekly
- Denosumab dosing? â Q6 mo SC
- Teriparatide duration? â 2 yr lifetime
- Romosozumab duration? â 12 monthly doses
- Glucocorticoid + osteoporosis? â #1 secondary
- Pagetâs marker? â ALP âââ
- Pagetâs drug? â Zoledronic acid
- CKD-MBD treatment? â P binder + active Vit D + cinacalcet
- Denosumabæ¥å? â Rebound fracture; bridge bisphosphonate
â ïž AI èçš¿ã